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The antiestrogen tamoxifen (TAM) inhibits the growth of different estrogen receptor (ER)-negative cells. Recently, multiple
effects of TAM on mitochondrial bioenergetic functions have been pointed to explain its ER-independent cell death mechanisms.
We have shown that TAM and its major active metabolite 4-hydroxytamoxifen (OHTAM) induce depolarization of the mito-
chondrial membrane potential () and uncouple the mitochondrial respiration, depressing the oxidative phosphorylation effi-
ciency. To clarify the biochemical mechanisms underlying the changes in the regulation of ATP synthesis and yield, in this work we
evaluated the alterations of mitochondrial adenine nucleotides induced by both drugs and ascertained whether such changes could
reflect a specific inhibition of either the adenine nucleotide translocase (ANT) or the phosphate carrier, as well as the activation of
ATP hydrolysis due to  depolarization. We found that both antiestrogens caused a concentration-dependent decrease in mito-
chondrial ATP levels. Mitochondrial ADP and AMP were concomitantly increased with a subsequent decrease in the ATP/ADP or
ATP/AMP ratios. The total concentration of adenine nucleotides also changed. Additionally, both drugs decreased the ANT con-
tent of mitochondria, inhibited the phosphate carrier and induced ATP hydrolysis. However, the effects of TAM were more drastic
than those induced by OHTAM. Therefore, the depletion of ATP might result from an activation of ATP catabolism, as well as
from a decrease in the mitochondrial content of ANT and partial inhibition of the phosphate carrier. Our data may explain the ER-
independent effects and cytotoxicity of both drugs and, in agreement with other previous studies, suggest that OHTAM is much less
toxic to mitochondria than TAM.
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Tamoxifen1. Introduction
The antiestrogen tamoxifen (TAM) is widely used in
the treatment of breast cancer and has been recognized
as a cancer chemopreventive agent in high-risk women
(Neven and Vernaeve, 2000; Radmacher and Simon,2000). It is extensively metabolized in humans being
4-hydroxytamoxifen (OHTAM) its major active meta-
bolite, which has been found in high levels in both the
plasma and the tumor tissues (Daniel et al., 1984; Lien
et al., 1991). This metabolite has been reported to pos-
sess several hundred times more affinity toward estrogen
receptor (ER) as compared with TAM (Borgna and
Rochefort, 1981). Thus, OHTAM is accepted as a more
active drug than its precursor in retarding the estrogen-
dependent cell growth and proliferation of ER-positive
mammary tumours (Jordan et al., 1988; Osborne et al.,
1992). However, large clinical trials have indicated that
a favourable response to adjuvant therapy with TAM is
also observed in different cell types that lack the ER
(Couldwell et al., 1993; Croxtall et al., 1994; Charlier et
al., 1995), thereby suggesting that, at least in part, its0887-2333/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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antineoplastic action may not be related to the anti-
hormone properties of these drugs. Also, there are
clinically significant ER-independent TAM actions for
which the biochemical mechanisms still remain obscure.
Mitochondria, which dominate the intracellular scen-
ery of most animal cells as their total number per cell
usually far exceeds that of any organelle, are the site of
most ATP cell production (Pederson, 1999), that is
essential to maintain and regulate several physiological
functions (Gupta et al., 2001 and references therein).
Therefore, the amount of ATP available for the cell can
in turn be considered as one of the key events in pre-
serving cell integrity. Thus, chemicals causing mito-
chondrial damage and inducing depletion of ATP may
in turn cause cell dysfunction or even cell death.
Recently we have shown that TAM depresses the
oxidative phosphorylation efficiency and uncouples the
mitochondrial respiration (Cardoso et al., 2001) and
that OHTAM affects the phosphorylation capacity of
mitochondria in a slight way as compared with the
damaging effects of TAM (Cardoso et al., 2002). These
effects are essentially a consequence of the membrane
potential () depolarization due to an increase in the
proton leak through the mitochondrial inner membrane
(Cardoso et al., 2002). Therefore, the cytotoxicity of
these drugs is associated with ATP depletion via
impairment of mitochondria function related to 
and/or oxidative phosphorylation. However, although
the ATPsynthase couples the transport of the protons
across the membrane to the synthesis of ATP inside the
mitochondrial matrix, the phosphate for the phosphor-
ylation is imported into the mitochondria by the phos-
phate carrier and the ATP is exported to the cytosol in
exchange for ADP by the adenine nucleotide translocase
(ANT).
Since the TAM action on mitochondrial phosphoryl-
ation is not completely understood and its OHTAM
metabolite has been shown to possess growth inhibitory
activity, the aim of this work was mainly to evaluate the
alterations of mitochondrial energetic charge induced
by both drugs and ascertain whether such changes could
reflect a specific inhibition of either the ANT or the
phosphate carrier, as well as the activation of ATP
hydrolysis.2. Materials and methods
2.1. Chemicals
Bovine serum albumin (BSA), 4-(2-hydroxymethyl)-1-
piperazineethanesulfonic acid (HEPES), ethylene gly-
col-bis (b-aminoethyl ether) NNN0N0-tetraacetic acid
(EGTA), 5, 50-dithio-bis(2-nitrobenzoic acid), N-ethyl-
maleimide, oligomycin, 4-Hydroxytamoxifen (OHTAM),
tamoxifen (TAM) and ATP, ADP and AMP for HPLCanalysis were obtained from Sigma Chemical Co (St.
Louis, MO). Carbonyl cyanide p-trifluormethoxyphenyl-
hydrazone (FCCP) and sucrose were obtained from
Merck (Dramstadt, Germany). All other chemicals were
commercial products of the highest purity grade avail-
able and solutions were prepared in deionized ultra pure
water.
2.2. Preparation of rat liver mitochondria
Mitochondria were isolated from the liver of over-
night fasted Wistar rats (250–300 g) of either sex by
differential centrifugation as described elsewhere (Car-
doso et al., 2001), with slight modifications. Animals
were killed by cervical dislocation and the liver was
quickly homogenized. The homogenate was prepared in
250 mM sucrose, 10 mM HEPES (pH 7.4), 1 mM
EGTA and 0.1% (w/v) free fatty acid BSA. The liver
homogenate was centrifuged at 500g for 10 min at 4 C
and mitochondria were recovered from the supernatant
by centrifugation at 10 000g for 10 min. The mitochon-
drial pellet was resuspended twice in the washing med-
ium containing 250 mM sucrose, 10 mM HEPES, pH
7.2. Mitochondrial protein was determined by the biuret
method using BSA as the standard (Gornall et al.,
1949).
2.3. Mitochondrial respiration
The oxygen consumption of isolated mitochondria
was measured polarographically using a Clark-type
oxygen electrode (YSI model 5331, Yellow Spring Inst.),
in a 1 ml thermostated water-jacketed closed chamber
with magnetic stirring and connected to a suitable
recorder. OHTAM and TAM in ethanolic solutions (up
to 6 ml) were incubated for 3 min at 25 C in 1 ml of the
standard respiratory medium consisting of 130 mM
sucrose, 50 mM KCl, 2.5 mMMgCl2, 2.5 mM KH2PO4,
5 mM HEPES, 0.1 mM EGTA, pH 7.2, previously
supplemented with mitochondria (1 mg) and 4 mM
rotenone. State 4 respiration was initiated with 5 mM
succinate and ADP (150 nmol/mg protein) was added to
establish state 3 respiration. Respiration rates were cal-
culated assuming an oxygen concentration of 240 nmol
O2/ml in the experimental medium at 25
C.
For the titration experiments with carboxyatractilo-
side (CATR) the respiration of isolated mitochondria
(0.5 mg/ml) was determined at 25 C using also a Clark
oxygen electrode. The respiratory medium contained
200 mM sucrose, 5 mM succinate (sodium salt), 5 mM
rotenone, 5 mM KH2PO4 and 20 mM Tris–HCl (pH
7.4). The ANT content was determined by titrating the
rate of state 3 respiration with increasing concentrations
of CATR (Vignais, 1976). Mitochondria were pre-incu-
bated with CATR in the respiratory medium for 1 min
before ADP (0.1 mM) addition to initiate state 3664 C.M.P. Cardoso et al. / Toxicology in Vitro 17 (2003) 663–670
respiration. Plots of O2 consumption versus CATR
appeared biphasic, with an increasing inhibitory seg-
ment followed by a steady respiration indicating that
state 3 respiration was completely inhibited. The mito-
chondrial content of ANT was determined by the
amount of CATR required to completely inhibit state 3
respiration, assuming a 1:1 binding stoichiometry,
which was expressed as CATR content per mg mito-
chondrial protein (Roussel et al., 2000; Zhou et al.,
2001).
2.4. Enzymatic activities
ATP-synthase activity was determined by measuring
the pH changes of the medium associated with ATP
synthesis as reported by Moreno and Madeira (1991).
The reactions were carried out at 25 C in 2 ml of reac-
tion medium containing 130 mM sucrose, 50 mM KCl,
2.5 mM MgCl2, 5 mM KH2PO4, 0.5 mM HEPES, 0.1
mM EGTA, pH 7.2, supplemented with 2 mM rotenone,
150 mM ADP and mitochondria (1 mg). The experi-
ments were initiated by the addition of 5 mM succinate
and TAM and OHTAM were added to induce hydro-
lysis of the ATP produced following ADP phosphoryl-
ation by the mitochondria. ATPase activity was
estimated by monitoring the pH changes of the same
medium associated with ATP hydrolysis (Madeira et al.,
1974).
2.5. HPLC determination of adenylates
Adenine nucleotides (ATP, ADP and AMP) were
extracted using an acidic extraction procedure and
separated by reverse-phase HPLC as described by Sto-
chi et al. (1985). Briefly, the acidic extraction was per-
formed as follows: 1 mg mitochondria protein was
incubated in 1 ml standard respiratory medium con-
taining 130 mM sucrose, 50 mM KCl, 2.5 mM MgCl2,
2.5 mM KH2PO4, 5 mM HEPES, 0.1 mM EGTA, pH
7.2, supplemented with 4 mM rotenone. TAM or
OHTAM were added at the concentrations of 20, 40
and 60 nmol/mg protein. A control assay in the absence
of any of those drugs, was also carried out. After the
incubation period (3 min), 5 mM succinate was added
to induce state 4 respiration and, 2 min later, 150 nmol
ADP were added to the reaction vessel to induce state 3
respiration. After 1 min of reaction, 250 ml of the sus-
pension were added to 250 ml ice–cooled HClO4 0.6 M
(EDTA–Na 25 mM). After vortexing, this mixture was
centrifuged at 10 000 rpm for 2 min at 4 C in an
Eppendorf table centrifuge (UNIEQUIP UEC 14/B)
and the pellet was discarded. The supernatant was neu-
tralized with KOH 3 M (Tris 1.5 M) and centrifuged
again (10 000 rpm, 2 min) to precipitate all the KClO4
produced. The supernatant was then stored at 80 C
for further chromatographic analysis. All the extractionprocedure was carried out at 0–4 C to minimize degra-
dation of nucleotides. The chromatographic apparatus
was a Beckman System Gold, consisting of a binary
pump (model 126) and a variable UV detector (model
166), controlled by a computer. The detection wave-
length was 254 nm and the column was a Lichrospher
100 RP-18 (5 mM) from Merck (Darmstadt, Germany).
An isocratic elution with 100 mmol/l phosphate buffer
(KH2PO4) (pH 6.5) and 1.2% methanol was performed
with a flow rate of 1 ml/min. The time required for each
analysis was about 5 min.
2.6. Mitochondrial swelling
Mitochondrial osmotic volume changes were mea-
sured by the apparent absorbance changes at 540 nm,
with a Perkin-Elmer Lambda 6 UV/vis spectro-
photometer computer controlled (Norwalk, USA). The
reactions were carried out at 25 C in 2.5 ml of the
required isoosmotic media: 135 mM ammonium phos-
phate, 5 mM HEPES, 0.1 mM EDTA, 2 mM rotenone
(pH 7.2).3. Results
To assess whether TAM or OHTAM affect the mito-
chondrial bioenergetic charge, we determined the ATP,
ADP and AMP levels in rat liver mitochondria under
the action of different concentrations of both drugs. As
shown in Table 1, the pre-incubation of mitochondria
with TAM or OHTAM for 3 min, before energization
with succinate, causes a concentration-dependent decrease
in ATP levels, with concomitant increases in levels of
ADP and AMP in the mitochondrial population. The
total concentration of adenine nucleotides also changes.
Moreover, both drugs decrease the ATP/ADP and
ATP/AMP concentration ratios as a consequence ofTable 1
Changes in the concentrations of adenine nucleotides in rat liver
mitochondria induced by different concentrations of TAM and
OHTAMaATP ATP/ADP ATP/AMPControl 189.907.07 203.6297.77 9.880.042
TAM 20 139.191.83 11.260.078 6.960.042
TAM 40 81.953.07 2.460.014 2.800.007
TAM 60 25.975.59 0.5150.021 0.2750.021
OHTAM 20 166.723.82 12.750.17 5.700.078
OHTAM 40 118.774.18 6.720.007 5.730.050
OHTAM 60 73.921.55 2.280.009 1.200.007a Mitochondria (1 mg) in 1 ml of the standard respiratory medium
were previously incubated with different concentrations of TAM or
OHTAM (20, 40 and 60 nmol/mg protein) for 3 min and adenine
nucleotides concentrations were determined by HPLC, as described in
Section 2. Each value (nmol/mg protein) represents the meanS.D. of
at least three independent determinations.C.M.P. Cardoso et al. / Toxicology in Vitro 17 (2003) 663–670 665
ATP levels depletion and increases in ADP and AMP
levels. These effects are more pronounced with TAM as
compared to OHTAM, according to other observed
effects on mitochondrial bioenergetic functions (Car-
doso et al., 2001, 2002).
Our recent reports pointing to a decrease in the oxi-
dative phosphorylation capacity of mitochondria trea-
ted with either TAM or OHTAM, as a consequence of
proton leak across the mitochondrial inner membrane
(Cardoso et al., 2001, 2002), led us also to investigate
whether the ANT and/or the phosphate carrier areinvolved in changes of oxidative phosphorylation effi-
ciency induced by both drugs. Thus, to assess the
involvement of ANT, titrations with CATR, an inhi-
bitor of the mitochondrial ANT, were performed. Rat
liver mitochondria were pre-incubated with TAM or
OHTAM (20 and 40 nmol/mg protein) and the results
are shown in Figs. 1 and 2. In both cases, either with
TAM (Fig. 1A) or with OHTAM (Fig. 1B), the ANT
sites were blocked by lower concentrations of CATR
than in the control assay without drugs, suggesting that
both drugs could affect the phosphorylation efficiency
by interference with the ANT.
CATR reacts with the ANT in a 1:1 stoichiometry
(Vignais, 1976; Klingenberg et al., 1975; Zhou et al.,
2001). Accordingly, the ANT content in mitochondria
can be estimated by titrating the active-state respiration
with CATR as illustrated in Fig. 1. The mitochondrial
content of active ANT was determined by the amountFig. 1. Determination of mitochondrial ANT content by titration of
active respiration with carboxyatractiloside (CATR). Mitochondria
(0.5 mg) in 1 ml of the respiratory medium containing 200 mM
sucrose, 5 mM succinate, 5 mM rotenone, 5 mM KH2PO4 and 20 mM
Tris–HCl (pH 7.4) were pre-incubated with different concentrations of
CATR during 2 min, after a previous incubation for 3 min, in the
absence (*) or presence of 20 (~) and 40 (~) nmol TAM/mg protein
(A) or 20 (~) and 40 (~) nmol OHTAM/mg protein (B). The reaction
was started by the addition of 0.1 mM ADP to initiate state 3
respiration and mitochondrial respiration rates were determined by O2
consumption with a Clark-type electrode. A representative pattern of
titration curves shows the method of estimation of ANT content.Fig. 2. ANT contents of mitochondria treated with TAM (A) or
OHTAM (B). The individual ANT contents were determined from the
types of experiments as shown in Fig. 1 and are expressed as pmol
CATR/mgmitochondrial protein. The values represent the meansS.D.
of three mitochondrial preparations.666 C.M.P. Cardoso et al. / Toxicology in Vitro 17 (2003) 663–670
of CATR required to reduce state 3 respiration to the
state 4 respiratory rate, when CATR presumably satu-
rates the translocase sites (Vignais, 1976), and the
results are shown in Fig. 2A and B. TAM decreases the
ANT content of mitochondria in a higher extension
than OHTAM in relation to the control (Fig. 2), i.e.,
mitochondria incubated without the drugs. In fact,
OHTAM and TAM at concentrations of 20 nmol/mg
protein induce decrease in the ANT content to about 81
and 64% of the control, respectively. Moreover, while
mitochondria pre-incubated with 40 nmol OHTAM/mg
protein still exhibit 67% of the ANT content, they only
exhibit 46% of this at the same concentration of TAM.
Such decrease in ANT content correlates with both the
decrease in phosphorylation efficiency of mitochondria
(Cardoso et al., 2002) and the changes in the ATP levels
induced by both drugs (Table 1). Therefore, the
mechanisms underlying the induced ATP depletion can
in theory be caused either by inhibition of ATP synth-
esis due to  depolarization or by changes in mito-
chondrial ANT content. However, either the putative
inhibition of the phosphate carrier or the degradation of
ATP to ADP and AMP can not be excluded.
In order to investigate the effect of both antiestrogens
on mitochondrial phosphate transport, the permeability
of the inner mitochondrial membrane in isoosmotic
medium of ammonium phosphate was analysed by
monitoring the mitochondrial swelling at 540 nm
(Fig. 3). After suspension in isoosmotic ammonium
phosphate, mitochondria swell spontaneously since,accompanying Pi accumulation, driven by its concen-
tration gradient, there is one proton entry, as dictated
by transport through the Pi carrier and matrix acid-
ification takes place causing accumulation of matrix
NH4
+ after diffusion of NH3 across the inner membrane
(Klingenberg, 1970; Klingenberg et al., 1974) (Fig. 3—
line a). Therefore, after NH3 permeation through the
mitochondrial membrane, the resulting ammonium
phosphate entry leads to the influx of water molecules
with the consequent mitochondrial swelling. In agree-
ment with this interpretation, any compound that
affects the phosphate carrier induces changes in the rate
of swelling of mitochondria in ammonium phosphate
medium. In fact, in the presence of N-ethylmaleimide
(Fig. 3—line f), an inhibitor of the phosphate carrier,
the mitochondrial swelling in isoosmotic medium of
ammonium phosphate is significantly decreased. In the
presence of TAM (Fig. 3—lines d, e) and OHTAM
(Fig. 3—lines b, c) a decrease occurs in mitochondrial
swelling, in a concentration-dependent way, suggesting
that both drugs cause a partial inhibition of the phos-
phate transport. This effect is higher for TAM accord-
ing to its stronger inhibitory effect in phosphorylation
efficiency, as compared with OHTAM (Cardoso et al.,
2001, 2002). Thus, we can infer that the depression of
ATP synthesis is partially related to the observed inhi-
bition of mitochondrial phosphate transport. Therefore,
we can conclude that the interference of TAM and
OHTAM with oxidative phosphorylation results not
only from the interference with ANT (Figs. 1 and 2) butFig. 3. Effects of TAM and OHTAM on swelling of mitochondria,
followed by monitoring the decrease in absorbance at 540 nm. Mito-
chondria (0.5 mg) were suspended in 2.5 ml of isoosmotic ammonium
phosphate medium containing 5 mM HEPES, 0.1 mM EDTA, 135
mM ammonium phosphate, 2 mM rotenone, pH 7.2. The reactions
were started at 25 C by the addition of mitochondria in the absence
(a) and presence of 20 (b) and 40 nmol (c) OHTAM/mg protein or 20
(d) and 40 (e) nmol TAM/mg protein or 2 mmol N-ethylmaleimide/mg
protein (f), added as indicated by the arrow. The traces are typical of
four experiments with different mitochondrial preparations.Fig. 4. Comparison of OHTAM and TAM effects on ATPase activity
of intact mitochondria. The experiments were carried out at 25 C in 2
ml of reaction medium containing 130 mM sucrose, 50 mM KCl, 2.5
mM MgCl2, 5 mM KH2PO4, 0.5 mM HEPES, 0.1 mM EGTA (pH
7.2), supplemented with 2 mM rotenone, 150 mM ADP and mitochon-
dria protein (1 mg). The reactions were started by the addition of 5
mM succinate and were monitored by following the production of
protons with a pH electrode. After phosphorylation of the added ADP,
TAM (80 nmol/mg protein), OHTAM (80 nmol/mg protein), FCCP (4
nmol/mg protein) and Triton X-100 (0.1%) were added as indicated by
the arrow. The traces are typical of three different experiments.C.M.P. Cardoso et al. / Toxicology in Vitro 17 (2003) 663–670 667
also from the partial inhibition of phosphate transport
into the mitochondria (Fig. 3).
In order to verify whether the effect of TAM and
OHTAM on mitochondrial ATP levels may also result
from an increase in ATP catabolism to ADP and AMP,
TAM and OHTAM were added to succinate-energized
mitochondria after ADP phosphorylation and the H+
consumption and production were followed by using a
pH electrode (Fig. 4). In fact, ADP phosphorylation by
mitochondria after addition of succinate is accom-
plished by H+ removal from the medium associated
with ATP synthesis (Fig. 4). The addition of TAM (80
nmol/mg protein) and OHTAM (80 nmol/mg protein),
as indicated by the arrows (Fig. 4), stimulate ATP
hydrolysis as proved by the release of H+ to the med-
ium, suggesting that both drugs increase the ATPase
activity of tightly coupled intact mitochondria. How-
ever, this effect induced by OHTAM is much smaller
than those promoted by FCCP (4 nmol/mg protein) and
TAM, which, like Triton (0.1%), induces disruption of
the mitochondrial inner membrane integrity (Cardoso et
al., 2001, 2002).4. Discussion
The cytotoxic effects of TAM in estrogen-dependent
breast cancer cells are mediated by high affinity binding
to the ER (Coezy et al., 1982). Previous studies have
reported that, in comparison with TAM, OHTAM has
higher affinity and specificity for the ER (Borgna and
Rochefort, 1981) and, besides being 100–200 times more
potent (Osborne et al., 1992; Jordan et al., 1988), it is
pharmacologically well tolerated (Sauvez et al., 1999).
Although most studies of TAM have centred on its
ability to compete with estrogens for binding to the ER
and thereby antagonize their ability to induce con-
formational change in the ER and therefore activate
transcription, several recent studies have described
additional ER-independent activities of TAM (Perry et
al., 1995; Fattman et al., 1998). In fact, TAM inhibits
also the growth of other cell types including ER-nega-
tive breast cancer cells (Jordan, 1990), lung adenocarci-
noma (Croxtall et al., 1994), prostate cancer (Bergan et
al., 1999), ovarian carcinoma (Trope et al., 2000), virus
(Laurence et al., 1990) and bacteria (Luxo et al., 1996).
Furthermore, in spite of several often-conflicting studies
showing that TAM and OHTAM can actively induce
programmed cell death in cancer cells (Dietze et al.,
2001; Mandlekar and Kong, 2001), it was reported that
both drugs could induce ER-dependent and -indepen-
dent programmed cell death (Obrero et al., 2002).
However, the ER-independent action mechanisms of
both drugs and their side effects have yet to be clarified.
Mitochondria of living cells participate in a number
of different processes, among which is ATP synthesis bythe oxidative phosphorylation system required to main-
tain the cell viability (Wallace and Starkov, 2000). ATP
synthesis occurs in the inner mitochondrial membrane
and requires the electron transport chain to generate the
electrochemical proton gradient (p) consisting of a
membrane potential () and a pH gradient (pH)
(Brown, 1992). Moreover, this complex process also
requires two key transport systems for the entry of ADP
and inorganic phosphate into the matrix space and the
ATPsynthase complex. On the other hand, almost all
intracellular ATP is generated in the mitochondria and
about one-third of the cellular adenine nucleotides are
located in these organelles (Pederson, 1999).
Recently, we have observed that TAM and, although
in a lesser extension, OHTAM induce both  depo-
larization, due to an increase in proton leak across the
inner mitochondrial membrane, and uncoupling the
mitochondrial respiratory chain, depressing the mito-
chondrial phosphorylative efficiency, as inferred from
the changes in the phosphorylative cycle induced by
ADP (Cardoso et al., 2002). However, it is noteworthy
that the oxidative phosphorylation is seriously compro-
mised at concentrations of TAM below those affecting
the electron transfer along the respiratory chain. There-
fore, in addition to the effects on redox chain and 
depolarization, these antiestrogens could affect the rate
of ATP synthesis as a consequence of ATP hydrolysis
stimulation and changes in either ANT or phosphate
carrier that use the components of p.
HPLC analysis of adenine nucleotides revealed that
indeed both antiestrogens decrease ATP levels, as well
as ATP/ADP and ATP/AMP concentration ratios and
increase ADP and AMP levels in the mitochondrial
population (Table 1). However, the effects induced by
TAM are more pronounced than those of OHTAM, in
agreement with our previous results (Cardoso et al.,
2002). In addition to the substantial alterations of
mitochondrial energetic charge promoted by these
drugs, the increase in the catabolism of ATP to ADP
and AMP (Fig. 4) may be a key factor involved in the
bioenergetic changes, rendering the mitochondria
unable to fulfil the cell energy requirements. Thus, these
effects reinforce that the hydrolysis of ATP (Fig. 4), in
addition to the  depolarization as consequence of
permeability to protons due to destructive effects in the
structural integrity of the mitochondrial inner mem-
brane (Cardoso et al., 2001, 2002), may also account for
the decrease in ATP levels induced by both drugs.
However, this decrease can also result from the partial
inhibition of both the ADP–ATP carrier (Figs. 1 and 2)
and the phosphate transport into the mitochondria
(Fig. 3). So, our data suggest that TAM and OHTAM,
in addition to the respiratory chain inhibition and
membrane proton leak with consequent depolarization
of  (Cardoso et al., 2002) disturb the mitochondrial
energetic charge (Table 1), affect the mitochondrial668 C.M.P. Cardoso et al. / Toxicology in Vitro 17 (2003) 663–670
transport of ADP (Figs. 1 and 2) and of Pi (Fig. 3), and
stimulate the ATPase activity (Fig. 4). Taken together,
these effects should be responsible for the observed
decreased efficiency in the phosphorylative capacity of
mitochondria induced by these drugs. It is noteworthy
that in agreement with other previous studies, OHTAM
is much less toxic to mitochondria than TAM.
In conclusion, the reduction in ATP levels induced by
these drugs can dictate the future of the cell and the
decision of the cell to undergo apoptosis and/or necro-
sis. Although these effects may not be specific for cancer
cells, they may account for the antiproliferative ER-
independent action mechanisms and for the cytotoxic
effects of these drugs in different cell types.Acknowledgements
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